Logo image of SLRN

ACELYRIN INC (SLRN) Stock Fundamental Analysis

NASDAQ:SLRN - Nasdaq - US00445A1007 - Common Stock - Currency: USD

2.27  +0.04 (+1.79%)

After market: 2.25 -0.02 (-0.88%)

Fundamental Rating

3

Taking everything into account, SLRN scores 3 out of 10 in our fundamental rating. SLRN was compared to 559 industry peers in the Biotechnology industry. SLRN has a great financial health rating, but its profitability evaluates not so good. SLRN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SLRN has reported negative net income.
In the past year SLRN has reported a negative cash flow from operations.
SLRN Yearly Net Income VS EBIT VS OCF VS FCFSLRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

The Return On Assets of SLRN (-61.52%) is comparable to the rest of the industry.
SLRN has a Return On Equity (-65.94%) which is in line with its industry peers.
Industry RankSector Rank
ROA -61.52%
ROE -65.94%
ROIC N/A
ROA(3y)-40.72%
ROA(5y)N/A
ROE(3y)-44.79%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLRN Yearly ROA, ROE, ROICSLRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

SLRN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLRN Yearly Profit, Operating, Gross MarginsSLRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for SLRN has been increased compared to 1 year ago.
There is no outstanding debt for SLRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SLRN Yearly Shares OutstandingSLRN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M 80M 100M
SLRN Yearly Total Debt VS Total AssetsSLRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of 1.25, we must say that SLRN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SLRN (1.25) is better than 68.93% of its industry peers.
SLRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.25
ROIC/WACCN/A
WACCN/A
SLRN Yearly LT Debt VS Equity VS FCFSLRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

SLRN has a Current Ratio of 18.43. This indicates that SLRN is financially healthy and has no problem in meeting its short term obligations.
SLRN's Current ratio of 18.43 is amongst the best of the industry. SLRN outperforms 91.79% of its industry peers.
SLRN has a Quick Ratio of 18.43. This indicates that SLRN is financially healthy and has no problem in meeting its short term obligations.
SLRN's Quick ratio of 18.43 is amongst the best of the industry. SLRN outperforms 91.96% of its industry peers.
Industry RankSector Rank
Current Ratio 18.43
Quick Ratio 18.43
SLRN Yearly Current Assets VS Current LiabilitesSLRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for SLRN have decreased strongly by -15.00% in the last year.
EPS 1Y (TTM)-15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SLRN will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.97% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y26.89%
EPS Next 2Y15.37%
EPS Next 3Y8.54%
EPS Next 5Y12.97%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLRN Yearly Revenue VS EstimatesSLRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SLRN Yearly EPS VS EstimatesSLRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SLRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLRN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLRN Price Earnings VS Forward Price EarningsSLRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLRN Per share dataSLRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.37%
EPS Next 3Y8.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLRN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACELYRIN INC

NASDAQ:SLRN (5/20/2025, 8:00:02 PM)

After market: 2.25 -0.02 (-0.88%)

2.27

+0.04 (+1.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11
Inst Owners89.36%
Inst Owner Change-15.13%
Ins Owners1.13%
Ins Owner Change-2.05%
Market Cap229.16M
Analysts85
Price Target8.16 (259.47%)
Short Float %4.79%
Short Ratio4.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.26%
Min EPS beat(2)-7.84%
Max EPS beat(2)10.36%
EPS beat(4)2
Avg EPS beat(4)-1.58%
Min EPS beat(4)-11.91%
Max EPS beat(4)10.36%
EPS beat(8)5
Avg EPS beat(8)5.07%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.28%
EPS NY rev (1m)0%
EPS NY rev (3m)7.74%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-2.99
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)-2.84
FCFYN/A
OCF(TTM)-2.83
OCFYN/A
SpS0
BVpS4.03
TBVpS4.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.52%
ROE -65.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.72%
ROA(5y)N/A
ROE(3y)-44.79%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 248.03%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.43
Quick Ratio 18.43
Altman-Z 1.25
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.78%
EPS Next Y26.89%
EPS Next 2Y15.37%
EPS Next 3Y8.54%
EPS Next 5Y12.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-77.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-79.09%
OCF growth 3YN/A
OCF growth 5YN/A